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Background. Mood, baseline functioning, and cognitive abilities as well as psychotropic medications may contribute to mortality
in adults with and without Down Syndrome (DS). Methods. Population-based (nonclinical), community-dwelling adults with
intellectual disabilities (IDs) were recruited between 1995 and 2000, assessed individually for 1–4 times, and then followed by
yearly phone calls. Results. 360 participants (116 with DS and 244 without DS) were followed for an average of 12.9 years (range
0–16.1 years as of July 2011). 108 people died during the course of the followup, 65 males (31.9% of all male participants) and
43 females (27.6% of all female participants). Cox proportional hazards modeling showed that baseline practical skills, seizures,
anticonvulsant use, depressive symptoms, and cognitive decline over the ﬁrst six years all signiﬁcantly contributed to mortality,
as did a diagnosis of DS, male gender, and higher age at study entry. Analysis stratiﬁed by DS showed interesting diﬀerences in
mortality predictors. Conclusion. Although adults with DS have had considerable improvements in life expectancy over time, they
are still disadvantaged compared to adults with ID without DS. Recognition of potentially modiﬁable factors such as depression
may decrease this risk.
1.Introduction
Although much improvement has occurred during the last
century, mortality rates in people with childhood onset in-
tellectual disabilities (IDs) are still higher than those of the
general population, especially in younger adults in their
20s and people with Down syndrome (DS) [1]. In general
populations, increased age is known to be an important
predictor of increased mortality, as is male gender, although
some data suggests that males with DS may have a relative
survival advantage [2]. In general, mortality rates are lower
in community samples, although this may not be true for
those with severe disabilities, whose needs may be met less
well in the community [3, 4].
Also of potential signiﬁcance to mortality is the Intel-
ligence Quotient (IQ). Among people with ID, those with
the most severe impairment were found in Patja et al’s
cohort study (previously referenced) to have signiﬁcantly
lowerlifeexpectancy,whereasthosewithmildIDhadsimilar
life expectancy to the general population. This diﬀerence
in life expectancy is likely related to increased severity
of underlying medical illness in those with the greatest
intellectual impairment.
In the general population, excess mortality (especially
due to cardiac and respiratory diseases) has been found in
those with major mental illness [5], case level depression
[6] and those who have depressive symptoms and medical
illness such as unstable angina [7]. Depressive symptoms
have been linked to decreased total active (and total) life
expectancy [8, 9], with some suggestions by Win et al. that
some of this is mediated by physical inactivity. Other reports
have linked autonomic dysfunction and inﬂammation to
the increased cardiovascular mortality risk associated with
depression [10]. Depressive symptoms have also been linked2 Current Gerontology and Geriatrics Research
to an increased risk of dementia in the general population
[11] and in a DS population [12], but reasons for this
association have not fully been clariﬁed. It is possible
that depression is itself a very early manifestation of the
development of a degenerative process such as Alzheimer’s
disease, but it may also exert (directly or indirectly) adverse
eﬀects on the biological structures in the brain, causing or
accelerating the degenerative process of dementia (although
recent neuropathological work by Tsopelas et al. [13]m a k e s
the latter explanation less likely). Dementia in turn has been
associatedwithincreasedmortalityinthegeneralpopulation
[14].
Other potential contributors to mortality include the
use of psychotropic medications. There has been particular
concernabouttheuseofantipsychoticmedicationsinpeople
with dementia, with some studies (but not all) suggesting
increased mortality and strokes (see review by [15]). Associ-
ations between antipsychotics and adverse health outcomes
are clearly not speciﬁc to people with dementia, as shown in
general population studies of increased sudden cardiac death
related to antipsychotics [16]. Adults with ID are commonly
prescribed antipsychotics [17–20], often for behavioural
problems,andmaythereforebeparticularlyimpactedbythis
adverse outcome.
Anticonvulsants are another potential contributor to
increased mortality. Although epilepsy itself is associated
with increased mortality including sudden unexplained
death [21–23] and new onset seizures are thought to be
markers for cognitive decline in people with DS (see review
in [24]), recent epidemiologic and placebo-controlled trials
data suggest that increased rates of death, especially violent
death including suicides, may be related to anticonvulsants
themselves [25, 26]. As anticonvulsants are used frequently
in people with ID, who have a high rate of epilepsy as well as
behavioral problems for which anticonvulsants are used, this
might be an important and potentially modiﬁable factor in
improving mortality rates.
The population-based (nonclinical), Intellectual Disabil-
ity and Aging Study was designed in the early 1990s to ﬁll
gaps in clinical understanding of longitudinal cognitive and
functionalchangesaswellasmortalitypatternsinadultswith
Down Syndrome (DS). After the methodology was discussed
at various university and community forums, adults with ID
butnotDSwereaddedtothestudytoprovideanappropriate
control group. This paper focuses particularly on baseline
contributors to mortality.
2. Methods
Appropriate authorization for whole study was obtained
from the University of Saskatchewan Ethics Committee.
Procedures followed were in accordance with the ethical
standards of the Helsinki Declaration of 1975, as revised in
2000 [27]. Letters requesting participation of any adult with
caregiver (or family) deﬁned childhood onset intellectual
disability aged 18 years and over were sent in 1995 to all
provincial community services (group homes, independent
living organizations, supportive work settings) designated
for adults with ID. There were no additional exclusion
criteria. Information was provided about the study, and
clinical coordinating staﬀ was asked to forward enclosed
consent forms to potential participants or their usual
substitute decisionmakers for medical decisions. Participants
who clearly understood the process of the study were asked
to provide their own consent. If the potential participant
assented but obviously lacked capacity for full, informed
consent, the person who normally consented to health
care interventions provided consent. If there was assent
but partial or unclear capacity to consent, both the per-
son and their usual medical decisionmaker would provide
consent. No participants were included whose family or
immediate caregivers voiced opposition to participation
after full information was provided. Participants or their
substitute decisionmakers mailed signed consent forms back
in provided envelopes. Research staﬀ made periodic phone
contact as necessary with community service providers to
provide further information about the study and to answer
questions about eligibility and appropriate provision of
c o n s e n t .O n ee x c e p t i o nw a sm a d et oa c c e p ta1 7y e a ro l d
participant whose substitute decision-maker mailed in a
consent form.
Once completed consent forms were received, question-
naires addressing basic demographics, residential informa-
tion (type of living situation), name of family physician,
psychiatric care, name of social services case manager,
basic health information (including suspected or conﬁrmed
dementia), seizure history and frequency of current seizures,
medication use, estimated level of disability (profound,
severe, moderate, mild, and borderline), and most recent IQ
score before the age of 18 were mailed to the care provider
who was most familiar with the participant. Care providers
were also mailed copies of standardized caregiver-rated
instruments (described in the following) to complete. After
receiving the completed questionnaires and instruments,
research staﬀ contacted care providers to assess the partic-
ipant’s ability and/or willingness to engage in direct inter-
views and testing. 276 participants eventually had at least
one direct assessment consisting of a variety of instruments,
which are not described here as they were not used in the
analysis forming the basis of this paper. All information was
reviewedbytheprimaryinvestigator,andadditionalcontacts
were made with care staﬀ, families, and medical staﬀ as
necessary to conﬁrm accuracy of information.
To establish to representativeness of our initial sample,
we obtained baseline 1995 service provision data (numbers
and age distribution) from the division of the Department of
Social Services responsible for people with ID, as our sample
was drawn from people participating in those services.
No ﬁnancial reimbursement was given to participants,
but at each wave of direct data collection a printed certiﬁcate
of participation was presented.
2.1. Data Collection. Formal instruments used in the study
were chosen for their ease of administration, acceptability,
validity, and psychometric data and had to be further
amended by the funding and manpower available. Final
instrumentsincludedinthecaregiverpackagewereEvenhuis’Current Gerontology and Geriatrics Research 3
Dementia Questionnaire for Persons with Mental Retarda-
tion (DMR: [28]) and the Reiss Screen for Maladaptive Be-
havior [29].
2.2. Dementia Questionnaire for Persons with Mental Retar-
dation (DMR). The Evenhuis questionnaire was chosen for
the evaluation of cognitive and functional decline in those
with ID as it was one of the practical and well-known
caregiver-rated instruments designed for this purpose, and
our study did not have resources to provide comprehensive
individualized dementia diagnoses to participants across the
province. The standardized 50-item instrument is based on
the dementia criteria in the DSMIII-R [30]b u tw a sa d a p t e d
to allow for easier scoring in those with baseline intellectual
disabilities. Higher scores on the DMR (based on behaviour
over the last three months) indicate more impairment.
Subscales of the DMR include short-term memory, long-
term memory, spatial and temporal orientation, speech,
practical skills, mood, activity and interest and behavioural
disturbance.
The DMR subscales themselves have been summed to
derive two major subscales: the Sum of Cognitive Scores
(SCS: short-term memory, long-term memory, spatial and
temporal orientation), which have a score range of 0 to 44,
and the Sum of Social Scores (SOS: speech, practical skills,
mood, activity and interest and behavioral disturbance),
whichhasarangeof0to60.ThepreferreduseoftheDMRin
the screening for dementia is by analyzing longitudinal score
changes, as the baseline IQ aﬀects most of the items in the
DMR. Evenhuis’ published criterion for a positive dementia
screen on the basis of longitudinal score changes is either an
increase of the SCS of 7 points or more and/or an increase of
the SOS of 5 points or more over subsequent tests.
Manpower was not available to provide individual
medical assessments and diagnosis of cognitive impairment
and/or dementia. We therefore decided to use individual
measures of yearly decline on the SCS and the SOS from
scores on the ﬁrst four detailed assessments for each
participant in the study, using the least squares method
[31]. This results in a separate slope for each individual
representing change over time in each subscale. The formula
used to derive the slope is shown as follows
Slopei =
4
j=1

xij −xi

yij − yi

4
j=1

xij −xi
2 . (1)
In this equation, for n participants who had 4 tests each,
yij represents the outcome for the ith participant at the
jth time, and xij is the independent variable for the ith
participant at the jth time. yι represents the mean outcome
for the ith participant, and xι represents the mean value of
the independent variable for the ith participant. We were
aware that slopes derived with this method would capture
only individual changes pooled over all of their ﬁrst four
assessments, rather than individual changes between speciﬁc
assessments, and felt that this was a reasonable approach as
individualsoccasionallyhadﬂuctuationsintheirfunctioning
in speciﬁc tests due to medical or social reasons.
2.3. The Reiss Screen for Maladaptive Behaviour (RSMB).
The 38-item Reiss Screen for Maladaptive Behavior [29]w a s
chosen to screen for depressive symptoms because it was
a well-known, caregiver-rated scale for people with ID
(not necessarily old), whose scores on its various subscales
could be compared to normative data, and correlated with
psychiatricsyndromesofclinicalinterest(inthiscasedepres-
sion). The eight core psychiatric subscales of the Reiss Scale
include aggressive behavior, autism, psychosis, paranoia,
depression (behavioral signs: anxious, crying spells, fearful,
overly sensitive, sadness), depression (physical signs: body
stress,eatingproblem,lowenergy,regressivebehaviour,sleep
problem), dependent personality disorder, and avoidant
personality disorder. Items were initially designed to be
completed by two separate caregivers who know the person
well, and ﬁnal scores on each category were to be based
on the average of the two scores. In clinical practice, the
ReissScreenisfrequentlycompletedbyonecaregiverbecause
of time constraints. Scores above the published cutoﬀ
scores for the individual subscales (aggression:5, autism:4,
psychosis:5, paranoia:5, depression (behavioral signs):5,
depression (physical signs):4, dependent personality disor-
der:6, and avoidant personality disorder:5) indicate clinical
problems and the need for a further clinical assessment.
Good psychometric properties were described by Reiss et al.
in [29], although abnormal scores in subscales are clearly
not analogous to standard clinical diagnoses. Some concerns
have more recently been expressed about the characteristics
of many screening instruments, including the Reiss Screen,
in people with ID [32]. However, at the time this study was
conceived, it was not possible to administer more detailed or
comprehensive assessments.
2.4. Data Management and Analysis. Full data were collected
from four formal data-assessment waves (1995-1996, 1997,
1999, and 2001), and limited data (mortality, nursing home
placement) was collected from ongoing follow-up telephone
surveys, most recently in July 2011. All data were entered by
research assistants into a secure access database designed by
the principal investigator, and data accuracy was veriﬁed for
at least 25% of all data entries in each wave. Data in one wave
was reentered due to greater than 5% errors. Descriptive
results of the data were initially organized into tabular
and graphic forms, exploring the patterns of univariate
associationsbetweenbaselinevariablesincludingage,sex,DS
diagnosis, seizure history, and frequency of current seizures,
health problems (including baseline caregiver identiﬁed
conﬁrmed or suspected dementia), baseline cognitive and
psychiatric symptoms (from the DMR and the Reiss Screen),
psychotropic medication use, IQ score, and mortality. IQ
was dropped from the analysis because not enough valid
scores were available in the sample. The baseline DMR
practicalskillssubscalescorewaschosenasthemainmeasure
approximating the level of global deﬁcits at entry to the
study, acknowledging that this level of baseline skills would
represent both baseline adult abilities as well as decrements
from any preclinical degenerative processes. Level of ID
(borderline, mild, moderate, severe, and profound) was also4 Current Gerontology and Geriatrics Research
dropped from the analysis because the interrater agreement
across waves was low.
T h er e m o t eh i s t o r yo fs e i z u r e sm a yn o th a v eb e e na s
accurate as information pertaining to seizures in the recent
year, as there is known to be a high turnover in care staﬀ,
and many of our informants may have had mostly recent
information about the participants. However, caregivers
during the detailed assessments in waves 1 to 4 were asked to
provide their best answers to the current and past presence
of seizures based on all information available to them using
the following rating: 0—never a history of seizures, 1—
previously seizures but no seizures in the past year or more,
2—seizures occurring at the rate of less than one seizure
per month, 3—one to four seizures per month, 4—two to
six seizures per week, or 5—daily seizures. Seizures were
exploredintheregressionanalysisusinganumberofrecoded
variables:noseizureseverdocumented,seizurespresentator
before baseline, active seizures present at baseline, seizures
reported in any of the four active data collection waves and
seizures occurring during the followup but not at baseline
(new seizures).
2.5. Statistical Analysis. Survival analysis was used to assess
diﬀerential mortality during the course of the study. Par-
ticipants were followed for a maximum of 16 years, with
some (very few) leaving the study prematurely and some
dying prior to the most recent contact in July 2011. Cox’s
proportional hazards modeling technique [33]w a su s e dt o
assess diﬀerential mortality, as it allows for the analysis
of mortality rates based on diﬀerent lengths of followup,
adjusting for various independent variables in the regression
model. It was not possible to do a time-dependent analysis
for the independent variables as detailed data on most (such
as medication use, occurrence of seizures) was only available
for four waves of data collection, as described above. To
compensate for this shortcoming, we used both the variable
score at baseline and a recoded variable representing a
pooled measure of the variable. For example, baseline use
of antipsychotic medications was added into the model as
well as a variable coding for the presence of an antipsychotic
during any of the four detailed data collection waves. In the
case of seizures, where the new onset of seizures is known
to be associated with dementia in persons with DS, a third
variable was created to represent people who developed new
seizures after baseline.
Variables that were added to the initial Cox regression
model using SPSS version 19 [34] included DS (0,1), sex
(males = 1, females = 2), age (at baseline in years), number
of years followed, deceased as of July 2011 (0,1), DMR
practical skills subscale score (score 0–16), DMR Sum of
Social Scores change per year and DMR Sum of Cognitive
Scores individual change per year over waves 1–4, use
of medications (antipsychotics, anxiolytics, antidepressants,
sedative-hypnotics, anticonvulsants) at any of the four
detailed waves of data collection, seizure status as described
earlier, and the depression-related Reiss subscale scores at
baseline (depression—behavioral, depression—physical).
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Figure 1: Age distribution of study participants at baseline (N =
360).
Core variables based on DS diagnosis, age, sex, and DS-
Age interaction term were kept in every initial model regard-
less of statistical signiﬁcance. Terms were then removed
manually from the model in order of least statistical sig-
niﬁcance. Results are presented as hazard ratios and their
95% conﬁdence intervals. The proportionality assumption
was satisﬁed when tested using the log minus log test.
3. Results
Participantscamefromallareasoftheprovinceexceptforthe
far north, with the largest number originating from urban
centres, consistent with the population distribution of the
province. Participant living situations included Community
Living Division group homes, private care homes, mental
healthapprovedhomes,assistedlivingfacilities,independent
dwellings,familyhomes,andonelargercongregatelivingsite
(but not the provincial institution for ID).
Thisstudypopulationrepresentedasizableproportionof
the overall service population recorded by the Department
of Social Services in 1995. In 1995, 3214 people with
ID received services or 0.32% of the total population of
Saskatchewan based on the 1996 census. Our participants
represented 9.9%, 22.8%, 17.4%, and 9% of this ID service
population within age groups 21–35, 36–54, 55–64, and 65+,
respectively.
The 360 participants providing data between 1995 and
2011 included 142 non-DS males, 102 non-DS females, 64
DS males, and 52 DS females. More males than females
entered the study (female to male ratio: 1:1.34), and the
DS group was about three years younger on average than
the non-DS group (P<0.05 using independent samples t-
test). Males and females were not signiﬁcantly diﬀerent in
age. Basic demographics are shown in Table 1 and shown
graphically in Figure 1.
Baseline scores on key variables entered into the initial
model are shown in Tables 2 and 3.
At the most recent analysis in July 2011, 108 participants
had died, and 9 had withdrawn for various reasons, leaving
243 in active followup. Follow-up time varied from 0 (onlyCurrent Gerontology and Geriatrics Research 5
Table 1: Demographics of participants at entry to the study.
Non-DS DS All diagnoses
Age Male Female Total Male Female Total Male Female Total
<30 24 16 40 13 7 20 37 23 60
30–39 42 32 74 22 19 41 64 51 115
40–49 39 26 65 19 17 36 58 43 101
50–59 21 16 37 8 7 15 29 23 52
6 0 – 6 9 7 1 0 1 7 2249 1 2 2 1
7 0 – 7 9 82 1 0 00082 1 0
8 0 – 8 9 101000101
Total 142 102 244 64 52 116 206 154 360
Mean 43.17 42.91 43.06 39.73 40.48 40.07 42.1 42.09 42.09
SE 1.18 1.23 0.85 1.27 1.35 0.92 0.91 0.94 0.65
Range 17–83 20–71 17–83 20–61 20–61 20–61 17–83 20–71 17–83
Table 2: Summary of key variables entered into the survival model (categorical variables).
Variable Variable detail Non-DS DS Total
Deceased As of July 2011 66 27% 42 36.2% 108 30.0
Dementia Caregiver reported at baseline 1 0.4% 6 5.2% 7 1.9
Medications
Antipsychotic at baseline 58 23.8% 37 31.9% 95 26.4
Antipsychotic in any wave 83 34% 49 42.2% 132 36.7
Antidepressant at baseline 30 12.3% 17 14.7% 47 13.1
Antidepressant in any wave 56 23% 26 22.4% 82 22.8
Sedative-hypnotic at baseline 5 2% 6 5.2% 11 3.1
Sedative-hypnotic in any wave 24 9.8% 14 12.1% 38 10.6
Anxiolytic at baseline 25 10.2% 11 9.5% 36 10.0
Anxiolytic in any wave 50 20.5% 26 22.4% 76 21.1
Anticonvulsant at baseline 66 27% 36 31% 102 28.3
Anticonvulsant in any wave 81 33.2% 48 41.4% 129 35.8
Seizure history
Seizure history (current or past) at baseline 84 34.4% 14 12.1% 98 27.2
Seizures (actively) present at baseline 39 16% 6 5.2% 45 12.5
Seizures reported in any of the four waves 80 32.8% 46 39.7% 126 35
New seizures reported after baseline 16 6.6% 12 10.3% 28 7.8
∗Higher scores indicate greater deﬁcits.
∗∗Higher scores indicate greater yearly increase in deﬁcits between 1995 and 2001.
one assessment before leaving the study for any reason) to
16.1 years as of July 2011, with the mean of 12.93 (0.21) years
(Figure 2).
The number and percentages of deceased participants
and mean ages of death and various categories are shown in
Table 4.
Based on Cox proportional hazards models with the
pooled DS and non-DS participants, leaving in the almost
signiﬁcant (P = 0.08) DS-age interaction term, sex, age at
baseline, baseline practical skills deﬁcits, baseline depression
symptoms (Reiss behavioural depression), yearly decline
on DMR social skills, a seizure history at baseline, a
seizure history at any point before and during the study,
and anticonvulsant use at baseline were all independently
statistically signiﬁcant to the prediction of mortality, as
shown in Table 5. The derived seizure variable, new seizure,
representing seizures arising after the beginning of the study,
was not signiﬁcant to mortality prediction. The use (baseline
orduringanyoftheﬁrstfourwaves)ofpsychotropicmedica-
tions including antipsychotics, antidepressants, anxiolytics,
andsedative-hypnoticswerealsonotsigniﬁcantpredictorsof
mortality. Also not signiﬁcant was the caregiver designation
ofsuspectedorconﬁrmeddementiaorcognitiveimpairment
at baseline.
A separate survival analysis (adjusting for DS, age, and
sex) was performed to explore whether the use of an
anticonvulsant during any of the ﬁrst four detailed data
collection waves in the absence of a current or previous
history of seizures increased mortality. Although there was
a trend supporting this, it was not signiﬁcant (P = 0.26).
Similarly, a separate survival analysis (adjusting for DS, age,
and sex) was conducted to explore the possibility that the6 Current Gerontology and Geriatrics Research
Table 3: Summary of key variables entered into the survival model (continuous variables).
Variable Variable detail
Non-DS DS Total
Mean (SE) Range Mean (SE) Range Mean (SE) Range
Years followed As of July 2011 13.26 (0.25) 0.59–16.10 12.26 (0.39) 0.0–16.05 12.93
(0.21) 0–16.10
Age Baseline 43.06 (0.85) 17–83 40.07 (0.92) 20–61 42.08
(0.66) 17–83
DMR (baseline)∗ Practical skills subscale
score 2.20 (0.24) 0–16 0.98 (0.22) 0–16 1.81 (0.18) 0–16
Reiss Screen baseline Depression (Behavioral) 1.30 (0.11) 0–8 0.93 (0.13) 0–7 1.18 (0.08) 0–8
Depression (Physical) 1.33 (0.10) 0–6 1.44 (0.16) 0–7 1.36 (0.09) 0–7
DMR change per
year∗∗
Sum of Cognitive Scores
(SCS) 0.33 (0.11) −5.26–13.14 0.71 (0.18) −2.12–11.99 0.45 (0.10) −5.26–13.14
DMR change per
year∗∗ Sum of Social Scores (SOS) 0.50 (0.12) −3.92–8.34 0.82 (0.23) −6.84–11.60 0.61 (0.11) −6.84 −11.60
∗Higher scores indicate greater deﬁcits.
∗∗Higher scores indicate greater yearly increase in deﬁcits between 1995 and 2001.
Table 4: Number (%) of the baseline cohort deceased and the mean age of death as of July 2011.
Sex
Non-DS DS All
Number (%)
deceased
Age of
death (SE)
Number (%)
deceased
Age of
death (SE)
Number (%)
deceased
Age of
death (SE)
Males 43 (30.3) 56.0 (2.0) 23 (35.9) 61.7 (2.6) 65 (31.9) 59.7 (1.6)
Females 29 (28.4) 61.6 (1.8) 13 (25.0) 60.1 (3.1) 43 (27.6) 58.6 (1.7)
All 66 (27.0) 61.1 (1.7) 42 (36.2) 56.3 (1.3) 108 (30.0) 59.2 (1.2)
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Figure 2: Length of follow-up of study participants by July 2011.
use of an antipsychotic in the absence of a clinical diagnosis
reported by a caregiver of a mental health problem for
which the use of an antipsychotic is generally appropriate
(any psychotic disorder such as schizophrenia or delusional
disorder, or bipolar disorder) might increase mortality. This
was also negative (P = 0.25).
Because people with DS are known to have shorter lifes-
pans and higher risks of dementia, even though the DS-Age
interaction was not quite signiﬁcant, the following analyses
were repeated with the groups stratiﬁed by DS. Table 6
shows that mortality in people without DS was predicted
by increased age, higher levels of Reiss physical depression
scores, greater decline in DMR social scores per year during
the ﬁrst four waves, and a seizure history at or before
baseline. Unlike in the pooled DS and non-DS analysis, sex,
baseline practical skills deﬁcits, baseline anticonvulsant use,
baseline Reiss behavioral depression, and seizure at any time
before or during the study were not signiﬁcant predictors of
mortality.
Cox regression for mortality in participants with DS re-
sulted in a diﬀerent model. Table 7 shows that mortality in
people with DS was increased by male sex, older baseline
age, increased baseline practical skills deﬁcits, higher levels
of baseline Reiss behavioural depression scores, and greater
declineinDMRcognitivescoresperyearduringtheﬁrstfour
waves.
Contrasts between some of the survival curves (adjusted
asshowninTables6and7)forparticipantswithandwithout
DS are illustrated in Figures 3, 4,a n d5.
4. Discussion
4.1. Pooled DS and Non-DS Analysis. Based on our pooled
DS and non-DS analysis (including the almost signiﬁcant
DS ∗ age interaction term), some of our ﬁndings regarding
the prediction of increased mortality, such as the presence
of DS, older age, and lower baseline level of baseline
functioning, do not challenge the general understanding
about mortality in ID. However, we did not ﬁnd that males
with DS had any special protection compared to females,
unlike some ﬁndings reported by others (cited earlier). We
instead found that males, just as in the general population,
had increased mortality when ﬁndings were adjusted for
the other signiﬁcant predictors including age and baseline
functioning.
We had not expected any impact of baseline depressive
symptoms on the eventual mortality when the study wasCurrent Gerontology and Geriatrics Research 7
Number of years followed since entry to study
20 15 10 5 0
C
u
m
u
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
1
0.8
0.6
0.4
0.2
0
Age 50 +
Age 40–49
Age 30–39
Age < 30
Survival function by age: non-DS
(a)
Number of years followed since entry to study
20 15 10 5 0
C
u
m
u
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
1
0.8
0.6
0.4
0.2
0
Survival function by age: DS
Age 50 +
Age 40–49
Age 30–39
Age < 30
(b)
Figure 3: Adjusted survival curves of 360 participants with ID (1995–2011): impact of baseline age: non-DS compared to DS.
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Figure 4: Adjusted survival curves of 360 participants with ID (1995–2011): impact of sex: non-DS compared to DS.8 Current Gerontology and Geriatrics Research
Table 5: Multivariate Cox regression analysis of mortality, as of July 2011.
β (SE) Sig. Hazard ratio (95% CI)
Down Syndrome −0.34 (1.00) NS 0.10–5.11
Sex (ref: male) −0.58 (0.23) <0.05 0.36–0.88
Baseline age 0.06 (0.01) <0.0001 1.05–1.09
Baseline DMR practical skills deﬁcits 0.09 (0.03) <0.005 1.03–1.16
Baseline Reiss behavioral depression 0.25 (0.06) <0.0005 1.12–1.44
Baseline anticonvulsant use 0.71 (0.33) <0.05 1.07–3.90
DMR Sum of Social Scores change per year 0.27 (0.05) <0.0001 1.18–1.45
History of seizure at or before baseline 0.50 (0.24) <0.05 1.04–2.63
Seizure before or during the study −0.69 (0.31) <0.05 0.28–0.91
Baseline age ∗ DS interaction 0.04 (0.02) 0.08 1.00–1.08
Table 6: Multivariate Cox regression analysis of mortality, as of July 2011 (Non-DS).
β (SE) Sig. Hazard ratio (95% CI)
Baseline age 0.06 (0.01) <0.0001 1.04–1.08
Baseline Reiss physical depression 0.19 (0.08) <0.05 1.03–1.41
DMR Sum of Social Scores change per year 0.34 (0.08) <0.0001 1.21–1.63
History of seizure at or before baseline 0.59 (0.28) <0.05 1.05–3.09
designed, and this association was found only after compre-
hensive exploration of all valid baseline variables in the Cox
regression analysis. The ID population is not known to have
highsuiciderates,andespeciallyinsupportivesettingsinour
community their level of preventive health care (and rates of
smoking) is likely better than that in the general population.
For example, most of our local community group homes
have excellent policies regarding yearly medical assessments
and screening. Self-harm attempts in people with depression
related to driving (inattention, purposeful risk-taking) are
also very unlikely in ID. The association between baseline
depressive symptoms and increased mortality in our study
is therefore consistent with previously cited data suggesting
that some other factors, such as inactivity, autonomic
dysfunction, and inﬂammation, may have an important role
to play. It is also possible that depressive symptoms are a
marker for early dementia, which is independently related to
increased mortality. However, the risk remained even when
adjusted for by yearly decline in social scores, as well as care-
giver direct reports of dementia or other cognitive functional
decline, so it would appear that depressive symptoms may
still have an additive adverse impact.
In our study, the use of antidepressants at baseline or
at any point in the ﬁrst four data collection waves did
not contribute signiﬁcantly in either direction to mortality.
Unfortunately, our data did not allow us to fully explore
whether the treatment of depression with antidepressants
(using a time covarying analytic technique) improved this
increased mortality risk, as we did not have data on
antidepressant use for the entire study period. This would
have been more ideal, as the data on treatment of depression
and mortality is contradictory, with some recent research,
such as that from the Women’s Health Initiative Study [35]
even suggesting an increased mortality and stroke risk in
women on these mediations.
The baseline use of anticonvulsants was associated with
increased mortality in our sample, even when adjusted for
seizures present at or before baseline and seizures present
at any time during the study. Anticonvulsants have many
adverse eﬀects, including drug-drug interactions, which may
have played a role. It would have been ideal to have detailed
information about the time of the original onset of seizures,
as this might have been signiﬁcant to eventual mortality out-
come. Although we did not ﬁnd that there was an additional
adverse impact on mortality by the use of anticonvulsants
in the absence of seizures, the potential red ﬂag of the
use of anticonvulsants suggests increased caution in using
thesedrugs,especiallyforbehavioralreasons,wherealternate
interventions might be instituted.
The presence of a seizure before or at baseline inde-
pendently increased mortality risk (P<0.05), as did the
presenceofaseizureatanypointduringthestudy(P<0.05).
The signiﬁcance of both of these predictors independently in
the model may suggest that both an early onset of seizures
and later seizures may have diﬀerent mechanisms of action
accountingfortheirassociationwithincreasedmortality,but
result in increased cumulative burden. For example, early
onset epilepsy is associated in sudden unexplained death
(cited earlier), and is also associated with other physical
problems which may increase mortality, whereas later onset
of seizures, especially in those with DS, is associated with
the development of dementia, itself a predictor of increased
mortality.
We did not ﬁnd that the baseline use (or use during any
of the ﬁrst four waves of detailed data collection) of antipsy-
chotics contributed to mortality, unlike some studies in frail,Current Gerontology and Geriatrics Research 9
Table 7: Multivariate Cox regression analysis of mortality, as of July 2011 (DS).
β (SE) Sig. Hazard ratio (95% CI)
Sex (ref: male) −0.98 (0.35) <0.01 0.187–0.75
Baseline age 0.10 (0.02) <0.0001 1.06–1.15
Baseline DMR practical skills deﬁcits 0.21 (0.07) <0.005 1.07–1.41
Baseline Reiss behavioral depression 0.27 (0.11) <0.01 1.07–1.62
DMR Sum of Cognitive Scores change per year 0.32 (0.08) <0.0005 1.17–1.63
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Figure 5: Adjusted survival curves of 360 participants with ID (1995–2011): impact of baseline functional deﬁcits: non-DS compared to DS.
demented people without ID. It is possible that healthier,
strong, people with ID may be more likely to exhibit risk
to others from aggressive behaviours and are therefore more
likely to be prescribed these agents. The prescription of
antipsychotics then might be a marker for decreased mor-
tality at baseline, masking any other direct adverse eﬀects.
We also did not ﬁnd an increased adverse impact of the
use of antipsychotics in the absence of a diagnosis of a
psychotic or bipolar disorder, for which antipsychotic use
is frequently indicated. Unfortunately, these diagnoses were
obtained from caregivers and chart information rather than
individual,standardizedassessments,sotheirvaliditymaybe
questionable.
Greater individual yearly changes in the DMR Sum of
Social Scores over the ﬁrst four data collection waves were
associated with increased mortality, even when adjusted for
by age and other factors. Although the yearly changes were
very small in all groups, this association suggests that, even
in young people, subtle decline in functioning might be
predictive of later, poor outcomes.
4.2. Stratiﬁed DS and Non-DS Analysis. Stratiﬁcation of the
analysis into participants with and without DS had face
value in light of the aging diﬀerences well established by
others, although the reduction in numbers likely resulted
in the loss of ability to ﬁnd signiﬁcance in some of the
potentially predictive factors for mortality. For example, the
use of anticonvulsants was no longer statistically signiﬁcant
to outcome in either group, sex was not signiﬁcant to
mortality in those without DS, and the impact of seizures10 Current Gerontology and Geriatrics Research
in those with DS (low numbers) could not be ascertained.
However, some patterns more speciﬁc to DS likely emerged
from this approach. Baseline practical skills deﬁcits were
strong predictors of mortality in DS but not in those without
DS, even when adjusted for by age, clinical diagnosis of
dementia, and other signiﬁcant predictive variables. This
diﬀerence could have arisen because participants with DS
may have had their baseline functioning already impaired
by early cognitive decline which was not recognized by
caregivers, and this decline itself increased mortality. Also
diﬀering between the DS and non-DS group was the type
of depressive symptoms found to be signiﬁcant predictors of
mortality. Baseline physical (rather than behavioral) symp-
toms of depression including body stress, eating problems,
low energy, regressive behaviour, and sleep problem were
predictive of increased mortality in participants without DS.
In contrast, in participants with DS, behavioural symptoms
of depression (anxious, crying spells, fearful, overly sensitive,
sadness) were found to be signiﬁcant predictors on increased
mortality. The reason for this discrepancy is not readily
apparent.
4.3. Study Limitations and Summary. Our study was limited
by small sample size, lack of sophisticated imaging, lack
of detailed data on causes of death, lack of medication
and seizure data throughout the whole study, and lack of
individualized and standardized clinical diagnosis. In spite of
this, the long follow-up time may provide valuable insights
into baseline predictors of serious health outcomes, and may
result in further improvements to life expectancy, especially
for those with higher mortalities or higher rates of depressive
symptoms. In particular, clinicians should take depressive
symptoms very seriously, evaluating associated health issues
and carefully the necessity for further consultation with
specialty services. The use of anticonvulsants for reasons
(such as behavioural problems) other than epilepsy should
be considered carefully, and perhaps only instituted if there
is a lack of response to other interventions. The presence
of seizures (early onset and later onset) is always a risk for
adverse health outcomes, yet excessive vigilance may also
result in decreased autonomous functioning and resultant
quality of life.
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